Epidemiology

Examining the prevalence and characteristics of depression, anxiety, apathy and cognitive impairment in Parkinson’s disease patients and their carers.

Assessment tools

Investigating the validity and reliability of depression and anxiety assessment methods in Parkinson’s disease. Developing a new instrument to assess anxiety in Parkinson’s disease.
 

Clinical diagnosis

Characterising symptomatology of depressive, anxiety, apathy and neurocognitive disorders in Parkinson’s disease.

Brain mechanisms and markers

Examining mechanisms underlying anxiety, depression, and neurocognitive disorders in Parkinson’s disease using resting state and task dependent EEG and fMRI.

Treatment

Developing and implementing new psychotherapy treatment for anxiety, depression, sleep, and chronic pain in Parkinson’s disease. Current packages include (i) cognitive behaviour therapy for anxiety, (ii) mindfulness, and (iii) interventions for sleep disturbances. 

Adverse effects (addiction)

Investigating addictive behaviours induced by dopaminergic medication in Parkinson’s disease patients: (i) impulse control disorders and (ii) dopamine dysregulation syndrome.